Basiliximab
Basiliximab
Basiliximab (pronounced as ba-si-lix-i-mab) is a monoclonal antibody used primarily in the prevention of early acute rejection episodes in renal transplantation.
Etymology
The name "Basiliximab" is derived from the Latin word 'basilica', meaning 'royal', and 'iximab', a suffix used in the naming of monoclonal antibodies.
Usage
Basiliximab is used in combination with cyclosporine, corticosteroids, and azathioprine in patients who are undergoing a kidney transplant. It works by blocking the action of a certain protein in the body that can affect the immune system, thus helping to prevent the body from rejecting the transplanted organ.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Acute Rejection: A type of organ rejection that occurs shortly after the transplant.
- Transplantation: The process of transferring cells, tissues, or organs from one site to another.
- Cyclosporine: A medication used to suppress the immune system and prevent the body from rejecting a transplanted organ.
- Corticosteroids: A class of drugs that lower inflammation in the body.
- Azathioprine: A medication used to prevent the body from rejecting a transplanted organ.
External links
- Medical encyclopedia article on Basiliximab
- Wikipedia's article - Basiliximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski